CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the …

CD8+ T cells are critical for elimination of cancer cells. Factors within the tumor
microenvironment (TME) can drive these cells to a hypofunctional state known as …

Chimeric antigen receptor (CAR) T cell therapy is revolutionizing cancer immunotherapy for
patients with B cell malignancies and is now being developed for solid tumors and chronic …

Virus-specific CD8+ T cells that differentiate in the context of resolved versus persisting
infections exhibit divergent phenotypic and functional characteristics, which suggests that …

Adaptive immune responses mediated by T cells and B cells are crucial for protective
immunity against pathogens and tumors. Differentiation and function of immune cells require …

Radiotherapy (RT) uses ionizing radiation to eradicate localized tumors and, in rare cases,
control tumors outside of the irradiated fields via stimulating an antitumor immune response …

Glycolysis, including both lactate fermentation and pyruvate oxidation, orchestrates CD8+ T
cell differentiation. However, how mitochondrial pyruvate metabolism and uptake controlled …

The success of chimeric antigen receptor (CAR) T cell therapy in treating several
hematopoietic malignancies has been difficult to replicate in solid tumors, in part because of …

T cells play a determining role in the immunomodulation and prognostic evaluation of
cancer treatments relying on immune activation. While specific biomarkers determine the …